A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

Johnson & Johnson (NYSE: JNJ) announced today that new data from its leading oncology pipeline will be presented at the American Urological Association (AUA) 2025 Annual Meeting, taking place April 26 ...

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

The following is a summary of “Comparison of hyperthermic intravesical chemotherapy using pirarubicin and Bacillus ...

First results from a Phase 3 trial conducted across 25 centers in Japan highlight Ferring’s ongoing commitment to establish ...

First results from a Phase 3 trial conducted across 25 centers in Japan were presented at the Annual Meeting of the Japanese Urological Association ...

Common childhood infections once considered mere inconveniences may provide unexpected long-term benefits. Emerging research suggests certain illnesses ...

In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...

But when cancer develops, it often uses tactics to fool the immune ... In this trial, the RUTI vaccine was administered alongside the standard BCG treatment. The results were promising: RUTI ...

A new systematic review explores how prehabilitation—through exercise, education, nutrition, and lifestyle changes—affects ...

ImmunityBio announces US FDA submissions of sBLA for NMIBC papillary disease and EAP for Anktiva to treat lymphopenia: Culver City, Calif Thursday, April 17, 2025, 15:00 Hrs [IST] ...